Mesa Laboratories, Inc.

Mesa Laboratories, Inc.

MLABNYSE / NASDAQTechnologySmall cap

$127.93-$5.48 (-4.1%)

Last close · Data as of Nov 20, 2026

Market cap
$602.9M
P/E
-305.4x
EV / EBITDA
17.9x
Revenue
$241.0M
Net margin
-0.8%
ROCE
6.1%

+78.7% over the last year

Mesa Laboratories, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+2.2%
3M
+7.4%
6M
+23.0%
1Y
+78.7%
5Y
-59.0%

52-week range

Day change -$5.48 (-4.1%) from $133 to $128 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in MLAB, bought on each weekday since 2021.

News & filings

What Mesa Laboratories filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 2.0 million US dollars in fiscal 2025.

Strengths (1)

  • Operating margin of 6.8% against a peer median of 1.6%.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.

Read moreShow less

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Sector
Technology
Shares outstanding
5.5M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$602.9M
P/E
-305.4x
P/B
3.8x
EV / EBITDA
17.9x
EV / Sales
3.1x
P/S
2.5x
52-week high
$142.23
52-week low
$70.60

Profitability

Operating margin
6.8%
Net margin
-0.8%
EBITDA margin
17.6%
ROE
-1.2%
ROCE
6.1%
ROIC
3.7%
ROA
-0.5%
Asset turnover
0.56

Growth

Revenue
$241.0M
Revenue growth, 1Y
11.5%
Revenue CAGR, 3Y
9.3%
Net profit growth, 1Y
-99.2%
Free cash flow
$42.3M

Solvency

Current ratio
0.63
Debt / Equity
1.14
Debt / Assets
0.42
CFO / Net profit
-23.71
Cash / Market cap
4.5%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$241.0M
Cost of revenue$90.1M
Gross profit$150.9M
Operating expenses$134.5M
Research and development$19.5M
Selling, general and administrative$115.0M
Operating income$16.3M
Interest and other-$10.4M
Pretax income$6.0M
Tax and other$7.9M
Net income-$2.0M

Revenue and net profit

Revenue grew 11.5% in FY2025; net profit is the dashed line.

Mesa Laboratories, Inc. revenue and net profit by fiscal year
Mesa Laboratories, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$184.3M$1.9M
FY2023$219.1M$930.0k
FY2024$216.2M-$254.2M
FY2025$241.0M-$2.0M

Cash flows

FY2025: $46.8M from operations, $42.3M free after investment (dashed).

Mesa Laboratories, Inc. operating and free cash flow by fiscal year
Mesa Laboratories, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$39.2M$34.8M
FY2023$28.0M$23.4M
FY2024$44.1M$41.6M
FY2025$46.8M$42.3M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$241.0M+11.5%1Y
EBITDA
$42.3M
Net profit
-$2.0M
Cash from operations
$46.8M+6.1%1Y
Free cash flow
$42.3M+1.8%1Y
Revenue CAGR, 3Y
9.3%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$241.0M$42.3M-$2.0M$42.3M-1.2%+11.5%-99.2%

Monthly returns

Month-by-month returns of MLAB across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$433.4M
Liabilities$273.5M
Equity$159.8M
Retained earnings-$188.9M

Market cap against peers

8 peers: same sector, nearest by size.

  1. VTEX$635.9M
  2. Mesa Laboratories, Inc. (this company)$602.9M

Peers map

Technology companies placed by value, growth and quality; MLAB highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Mesa Laboratories, Inc. (this company)3.1x

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Mesa Laboratories, Inc.MLABthis company$602.9M-305.4x3.8x-1.2%17.9x
VTEXVTEX$635.9M31.8x2.7x8.6%29.2x
Consensus Cloud Solutions, Inc.CCSI$632.2M7.5x45.9x613.7%6.7x
Clearfield, Inc.CLFD$604.6M-75.1x2.4x-3.1%40.0x
PAR Technology CorporationPAR$598.5M-7.1x0.7x-10.2%-34.6x
Grid Dynamics Holdings, Inc.GDYN$582.9M60.3x1.1x1.8%11.1x
PowerFleet, Inc.AIOT$567.4M—14.7x-11.4%37.9x
Cerence Inc.CRNC$557.2M—3.7x-12.4%57.5x
i3 Verticals, Inc.IIIV$554.7M31.0x1.4x4.6%11.5x
Peer median—19.3x2.5x-0.7%20.3x

Year-to-date ROI

MLAB since 1 January, against earlier years.

Historical volatility

MLAB's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Mesa Laboratories, Inc. operating margin by fiscal year
Mesa Laboratories, Inc. operating margin by fiscal year
DateOperating margin
FY20222.5%
FY20231.5%
FY20241.1%
FY20256.8%
LineFY2025
Cost of revenueCost Of Revenue$90.1M
Gross profitGross Profit$150.9M
Operating expensesOperating Expense$134.5M
Research and developmentResearch And Development$19.5M
Total expensesTotal Expenses$224.6M
Pretax incomePretax Income$6.0M

Learn while you research

Academy chapters picked for Mesa Laboratories, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Growth InvestingTech & communications often trade on growth, learn the framework.7 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →